6-三氟甲基-1H-吲唑-3-羧酸甲酯 | 877773-17-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 6-三氟甲基-1H-吲唑-3-羧酸甲酯
• 中文别名: 6-三氟甲基吲唑-3-羧酸甲酯
• 英文名称: methyl 6-(trifluoromethyl)-1H-indazole-3-carboxylate
• 英文别名: 6-trifluoromethyl-1H-indazole-3-carboxylic acid methyl ester
• CAS: 877773-17-6
• 化学式: C₁₀H₇F₃N₂O₂
• 分子量: 244.173
• InChiKey: VSKCVMICQDVGNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-三氟甲基-1H-吲唑-3-羧酸甲酯 在 四丁基碘化铵 甲醇 、 manganese(IV) oxide 、 lithium hydroxide 、 水 、 二异丁基氢化铝 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 反应 22.25h， 生成 (E)-3-(1-(2,4-dichlorobenzyl)-6-(trifluoromethyl)-1H-indazol-3-yl)acrylic acid
  参考文献：
  名称：

  Lonidamine analogues and their use in male contraception and cancer treatment

  摘要：

  用于抑制精子生成和癌症治疗的新化合物，特别是作为热休克蛋白和/或延长因子1α的抑制剂。

  公开号：

  US20060047126A1
• 作为产物：
  描述：

  4-氯-3-硝基三氟甲苯 在 5%-palladium/activated carbon 亚硝酸特丁酯 、 potassium tert-butylate 、 氢气 、 溶剂黄146 、 sodium chloride 作用下， 以 水 、 二甲基亚砜 、 甲苯 、 叔丁醇 为溶剂， 20.0~120.0 ℃ 、101.33 kPa 条件下， 反应 33.0h， 生成 6-三氟甲基-1H-吲唑-3-羧酸甲酯
  参考文献：
  名称：

  Lonidamine analogues and their use in male contraception and cancer treatment

  摘要：

  用于抑制精子生成和癌症治疗的新化合物，特别是作为热休克蛋白和/或延长因子1α的抑制剂。

  公开号：

  US20060047126A1

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR TRAITER DES ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ DE STING
  申请人：IFM DUE INC

  公开号：WO2022015938A1

  公开（公告）日：2022-01-20

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

  本公开涉及化学实体（例如，一种化合物或药用可接受盐，和/或水合物，和/或共晶体，和/或该化合物的药物组合），其抑制（例如，对抗）干扰素基因激活剂（STING）。所述化学实体可用于治疗病症、疾病或障碍，其中增加（例如，过度）STING激活（例如，STING信号传导）导致该病症、疾病或障碍的病理和/或症状和/或进展（例如，癌症）在受试者（例如，人类）中。本公开还涉及含有相同化学实体的组合物，以及使用和制备相同的方法。
• [EN] ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS<br/>[FR] DÉRIVÉS DE CARBOXAMIDE SUBSTITUÉS PAR ARYLE COMME INHIBITEURS DES CANAUX CALCIQUES OU SODIQUES
  申请人：RAQUALIA PHARMA INC

  公开号：WO2010137351A1

  公开（公告）日：2010-12-02

  The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S)blockers such as NaV1.3 and NaV1.7, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved.

  本发明涉及式(I)或其药物可接受的盐的芳基取代羧酰胺衍生物，其具有T型钙通道或电压门控钠通道的阻断活性，如NaV1.3和NaV1.7等Tetrodotoxin敏感（TTX-S）阻断剂，适用于治疗或预防涉及T型钙通道或电压门控钠通道的疾病和紊乱。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及T型钙通道或电压门控钠通道的疾病中使用这些化合物和组合物的用途。
• LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT
  申请人：Georg Ingrid Gunda

  公开号：US20110060003A1

  公开（公告）日：2011-03-10

  Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis in the subject; reduce testis weight in the subject; reduce ovary weight in a female subject; reduce serum progesterone in the female subject; impair ovarian follicle function in the female subject; causing reversible fertility in the subject. In order to return fertility, the method can include ceasing administration of the compound to the subject so as to return fertility in the subject. The compound can be administered for irreversibly sterilizing the subject.

  生育管理可以包括：根据公式I的一个或多个剂量给予受试者一种化合物，以降低受试者的生育能力。生育管理还可以包括给予化合物的有效量：破坏雄性受试者的精原细胞功能；抑制受试者的精子生成；减少受试者的睾丸重量；减少雌性受试者的卵巢重量；减少雌性受试者的血清孕酮；破坏雌性受试者的卵巢滤泡功能；导致受试者可逆的生育能力。为了恢复生育能力，该方法可以包括停止给予化合物以使受试者恢复生育能力。该化合物可以用于对受试者进行不可逆的绝育。
• ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS
  申请人：Inoue Tadashi

  公开号：US20120101105A1

  公开（公告）日：2012-04-26

  The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blockers such as Na v1.3 and Na v1.7 , and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved.

  本发明涉及公式(I)或其药学上可接受的盐的芳基取代羧酰胺衍生物，其具有T型钙通道或电压门控钠通道的阻滞活性，如Nav1.3和Nav1.7等Tetrodotoxin敏感(TTX-S)阻滞剂，并且在涉及T型钙通道或电压门控钠通道的疾病或疾病的治疗或预防中有用。本发明还涉及包含这些化合物的制药组合物以及在涉及T型钙通道或电压门控钠通道的疾病或疾病的预防或治疗中使用这些化合物和组合物的用途。
• Lonidamine analogues and treatment of polycystic kidney disease
  申请人：Georg Ingrid Gunda

  公开号：US08362031B2

  公开（公告）日：2013-01-29

  Lonidamine derivatives can be useful in methods of treating, inhibiting, and/or preventing polycystic kidney disease (PKD). Accordingly, lonidamine derivatives can be administered in a therapeutically effective amount for inhibiting, and/or preventing polycystic kidney disease (PKD) in the subject. This can include administering a therapeutically effective amount of the lonidamine derivatives for inhibiting CFTR and/or Hsp90 or biological pathway thereof. Also, the method can include administering the lonidamine derivatives in a therapeutically effective amount for inhibiting ErbB2, Src, Raf-1, B-Raf, MEK, Cdk4, NKCC1, or combinations thereof. For example, the therapeutically effective amount of the lonidamine derivatives can be configured so as to provide a concentration in or adjacent to a kidney cell of about 0.25 uM or more or less.

  Lonidamine衍生物可以用于治疗、抑制和/或预防多囊肾病（PKD）的方法中。因此，可以在治疗上对受体施用治疗有效量的Lonidamine衍生物以抑制和/或预防多囊肾病（PKD）。这可以包括施用治疗有效量的Lonidamine衍生物以抑制CFTR和/或Hsp90或其生物途径。此外，该方法可以包括施用治疗有效量的Lonidamine衍生物以抑制ErbB2、Src、Raf-1、B-Raf、MEK、Cdk4、NKCC1或其组合。例如，Lonidamine衍生物的治疗有效量可以被配置为在肾细胞内或相邻的浓度为大约0.25 uM或更高或更低。